Mastocytosis, Systemic: all 56 studies
Page 1 of 1. Open to participants first (16), then studies with results posted, then the rest; newest registration first within each.
- New Italian Mastocytosis RegistryRecruitingNCT07917156
- Precision Medicine for Indolent Systemic Mastocytosis (PRISM)Not yet recruitingNCT07757893
- Peripheral Blood KIT-D816V Mutation in Adult Systemic MastocytosisRecruitingNCT07562542
- An Observational Study in Participants With Indolent Systemic Mastocytosis (ISM)RecruitingNCT07264959
- A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in GermanyRecruitingNCT07255638
- Mastocytosis From Pediatric Age to Adulthood: Local Registry of Cutaneous and Systemic MastocytosisRecruitingNCT07142473
- Expanded Access to Bezuclastinib for Patients With NonAdvanced Systemic Mastocytosis or Advanced Systemic MastocytosisAvailableNCT06915766
- Avapritinib Rollover StudyRecruitingNCT06748001Phase 4
- Avapritinib With Decitabine in Patients With SM-AHNRecruitingNCT06327685Phase 1
- Angioedema Biomarker Research StudyRecruitingNCT06210698
- Evaluation of the DALY on a Cohort of Patients With Indolent Systemic MastocytosisRecruitingNCT05923372
- Observational Study for the Evaluation of Incidence of Systemic Mastocytosis in t(8;21) Acute Myeloid LeukemiaRecruitingNCT05504408
- (Apex) Bezuclastinib in Patients With Advanced Systemic MastocytosisRecruitingNCT04996875Phase 2
- (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic MastocytosisRecruitingNCT04910685Phase 2/3
- Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic MastocytosisRecruitingNCT04655118Phase 2
- Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic TreatmentRecruitingNCT04333108Phase 3
- Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic MastocytosisCompletedNCT03770273Phase 2Results posted
- (PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic MastocytosisCompletedNCT03580655Phase 2Results posted
- GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological MalignanciesTerminatedNCT03214666Phase 1/2Results posted
- Ibrutinib in Treating Patients With Advanced Systemic MastocytosisTerminatedNCT02415608Phase 2Results posted
- Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell LeukemiaCompletedNCT01807598Phase 2Results posted
- Obatoclax for Systemic MastocytosisTerminatedNCT00918931Phase 2Results posted
- Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell LeukemiaCompletedNCT00782067Phase 2Results posted
- Everolimus (RAD001) as Therapy for Patients With Systemic MastocytosisCompletedNCT00449748Phase 2Results posted
- Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell LeukemiaCompletedNCT00233454Phase 2Results posted
- A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic MalignanciesCompletedNCT00109707Phase 1/2Results posted
- Quality of Life and Disease-related Symptoms in Individuals With Systemic MastocytosisActive, not recruitingNCT06065007
- A Registry for Patients With Systemic Mastocytosis in ChinaStatus unknownNCT06013683
- Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic MalignanciesTerminatedNCT05609942Phase 1
- A Study of MGD024 in Patients With Relapsed or Refractory Hematologic MalignanciesActive, not recruitingNCT05362773Phase 1
- Managed Access Programs for PKC412, MidostaurinNo longer availableNCT05219266
- (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic MastocytosisActive, not recruitingNCT05186753Phase 2
- Retrospective Study Assessing the Effect of Avapritinib Versus Best Available Therapy in Patients With AdvSMCompletedNCT04695431
- Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological MalignanciesCompletedNCT04681105Phase 1
- Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood CancerWithdrawnNCT03739606Phase 2
- (PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic MastocytosisActive, not recruitingNCT03731260Phase 2
- Adaptation of the Questionnaire "Regarding Patient's Quality of Life With Mastocytosis" in the French LanguageCompletedNCT03632811
- Interest of Denosumab Treatment in Osteoporosis Associated to Systemic MastocytosisCompletedNCT03401060Phase 3
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002CompletedNCT02808793Phase 1
- Mast Cell Connect: A Registry for Patients With MastocytosisCompletedNCT02620254
- A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced MalignanciesCompletedNCT02571036Phase 1
- (EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid MalignanciesCompletedNCT02561988Phase 1
- Treatment of Indolent Systemic Mastocytosis With PA101CompletedNCT02478957Phase 2
- Diagnostic Value of Bone Marrow Tryptase in Systemic MastocytosisCompletedNCT02441166Not applicable
- Patient-Reported Outcome Questionnaire for Systemic MastocytosisCompletedNCT02380222
- Midostaurin in Indolent Systemic MastocytosisStatus unknownNCT01920204Phase 2
- Cladribine Plus Pegylated Interpheron Alfa-2a in Systemic MastocytosisStatus unknownNCT01602939Phase 2/3
- Use of Tamoxifen in Systemic MastocytosisCompletedNCT01334996
- Imatinib in KIT-negative Systemic MastocytosisCompletedNCT01297777Phase 4
- Evaluation of Response of Dasatinib to Treat MastocytosisStatus unknownNCT00979160Phase 2
- Masitinib in Severe Indolent or Smoldering Systemic MastocytosisCompletedNCT00814073Phase 3
- Thalidomide in Treating Patients With Relapsed or Progressive Systemic MastocytosisCompletedNCT00769587
- Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM)CompletedNCT00493129Phase 2
- Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase EnzymesCompletedNCT00171912Phase 2
- Cytokine Production Patterns in Patients With Systemic Mastocytosis Compared With Atopic Dermatitis and Healthy IndividualsCompletedNCT00001760
- Study of Mast Cell PrecursorsCompletedNCT00001756